CN102657899A - Medicament coating stent capable of preventing blood vessel restenosis and preparation method thereof - Google Patents
Medicament coating stent capable of preventing blood vessel restenosis and preparation method thereof Download PDFInfo
- Publication number
- CN102657899A CN102657899A CN2012101590609A CN201210159060A CN102657899A CN 102657899 A CN102657899 A CN 102657899A CN 2012101590609 A CN2012101590609 A CN 2012101590609A CN 201210159060 A CN201210159060 A CN 201210159060A CN 102657899 A CN102657899 A CN 102657899A
- Authority
- CN
- China
- Prior art keywords
- plga
- medicine
- preparation
- stent
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention provides a medicament coating stent capable of preventing blood vessel restenosis and a preparation method thereof. The stent is coated with a PLGA (polylactic acid-glycollic acid) nano particle coating which comprises a medicament carrier and a medicament material; the medicament carrier is PLGA; and the medicament material is one or two of rapamycin or paclitaxel. The preparation method comprises the following steps of: dissolving PLGA with dichloromethane, adding the medicament material, dissolving fully, and performing ultrasonic emulsification by use of an ultrasonic cell disruptor under an ice bath condition so as to prepare a suspension; slowly adding a 2% PVA (Polyvinyl Alcohol) water solution into the suspension while performing magnetic stirring, and emulsifying the suspension again so as to prepare an emulsion; performing rotary evaporation on the emulsion under reduced pressure so as to enable dichloromethane to volatilize completely, so that a nano particular colloidal dispersion system is obtained; adding a 1% coupling agent into the system, and then soaking the stent into the system for 5 minutes, so as to prepare the coating stent; and freeze-drying the coating stent for 10 hours, and preserving the freeze-dried stent at the temperature of 4 DEG C.
Description
Technical field
The present invention relates to the drug stent in medical material field, particularly relate to a kind of coating stent of medicine that prevents vascular restenosis and preparation method thereof.
Background technology
Atherosclerosis is to cause that luminal stenosis or obstruction are the main causes that causes ischemic heart desease.Percutaneous intracavity arterioplasty adopts sacculus full with inaccessible or narrow vasodilation, makes blood supply recover normally to be accepted and be applied to treat coronary heart disease widely.Though clinical effectiveness is satisfactory for arterioplasty in the bellows, its acute vascular obturation and postoperative blood vessel have limited its development to a certain extent narrow.
In order to solve this difficult problem of arterioplasty postoperative restenosis in the bellows; Medical circle is constantly innovated exploration both at home and abroad, and research worker is selected the polymer of those good biocompatibilities as medium, with medicament mixed therein; Be coated in rack surface, successful exploitation bracket for eluting medicament.Rack surface with medicine can implant that the back slowly discharges and keep effective treatment concentration of long period in the pathological changes part at support.So far, bracket for eluting medicament obtains establishing in the effect of control in-stent restenosis.
Traditional bracket for eluting medicament behind its implant into body, the release medicine that the medicament controlled-release coating through the surface slowly continues in stenosis, still, by the direct metabolism of blood vessel, utilization ratio of drug is low easily for medicine, and the blood medicine Css persistent period is undesirable.In addition, support carry with process of expansion in the destruction of generation medication coat easily, in case and medication coat destroys, then very likely cause the coating bulk to come off.Though present bracket for eluting medicament can significantly reduce in the bellows restenosis behind the artery angioplasty, incidence of thrombus raises in the late period support, has increased relevant acute myocardial infarction and dead the generation.
Summary of the invention
Based on this; Be necessary problem to the shortcoming of prior art; A kind of coating stent of medicine that prevents vascular restenosis and preparation method thereof is provided, has improved the adhesion of medication coat and rack surface, reduced the problem that medication coat comes off in slits and expansion; The nanoparticle size of coating medicine material has improved the holdup time of medicine at diseased region.
A kind of coating stent of medicine that prevents vascular restenosis and preparation method thereof; Be covered with nanoparticle coating on the said support; Said nanoparticle coating comprises pharmaceutical carrier and drug material; Said pharmaceutical carrier is polylactic acid-glycollic acid PLGA, and said drug material is one or both the mixing in rapamycin or the paclitaxel, and the mass ratio of said drug material and pharmaceutical carrier is 1:3～10;
The method for preparing of said coating stent of medicine comprises following step:
1., at first adopt water cutter engraving mode that said support is engraved as reticulate pattern hollow out tubular body;
2., treat that support engraving is accomplished after, through dichloromethane with said polylactic acid-glycollic acid PLGA dissolving formation PLGA dichloromethane solution;
3., in the PLGA dichloromethane solution, add said drug material; And fully dissolving in the PLGA dichloromethane solution; After treating said drug material dissolving; The PLGA dichloromethane solution that is dissolved with drug material is placed under the condition of ice bath, adopt Ultrasonic Cell Disruptor emulsifying 8～12 min to process suspension again;
4., after suspension preparation accomplishes, in said suspension, slowly add 1.5～2.5% PVAC polyvinylalcohol aqueous solutions, through magnetic agitation, the speed of magnetic agitation is 300 r/min when adding the PVA aqueous solution; And then adopt Ultrasonic Cell Disruptor emulsifying 8～12 min, make emulsion;
5., after emulsion preparation accomplishes, under 35～45 ℃ of temperature, with the emulsion decompression and the rotary evaporation that make, make in the emulsion the dichloromethane volatilization fully, and then make the nanometer colloid dispersion;
6., in said nanometer colloid dispersion, add 0.8～1.2% coupling agent; The support of engraving impregnated in 4～6 min in the nanometer colloid dispersion that adds coupling agent; Make coating stent of medicine; Then 10～12 h are handled in prepared coating stent of medicine lyophilization, after finishing dealing with, in 4 ℃ of preservations.
Among embodiment, said polylactic acid-glycollic acid PLGA comprises PLA and PGA, molar ratio 75～85:15～25 of said PLA and PGA therein.
Among embodiment, the optimum molar ratio of said PLA and PGA is 80:20 therein, and when the optimum molar ratio of said PLA and PGA, said polylactic acid-glycollic acid PLGA molecular weight is 35000～55000.
Therein among embodiment, said coupling agent is a kind of in silanes, titanate ester and the aluminic acid chemical compound.
Among embodiment, said support is the cochrome support therein.
Among embodiment, said rapamycin and paclitaxel mixed proportion are 1:1 therein.
Above-mentioned coating stent of medicine that prevents vascular restenosis and preparation method thereof; Said medication coat Chinese medicine material is the mixture of any or two kinds in rapamycin (RPM) and the paclitaxel; Said pharmaceutical carrier is polylactic acid-glycollic acid (PLGA), and PLGA is prepared to the nanoparticle size, and PLGA nanoparticle size evenly; Particle size distribution range is narrow, concentrates to be distributed in 100 ~ 200 nm.After the PLGA nanoparticle arrives target cell, interact with the target cell surface receptor, be transported to cell through modes such as endocytosis, the degraded through PLGA discharges medicine gradually, has improved the ability of medicine penetrate tissue.PLGA has the favorable biological degradability and the compatibility, and degradation speed is controlled, has improved the bioavailability of medication coat, has significantly improved drug material in the endovascular holdup time, keeps the long-time in vivo steady plasma-drug concentration of medicine.
Said coupling agent can improve the adhesion of medication coat and support, avoids said medication coat to come off.Said coupling agent reacts at said rack surface, not only can improve the adhesive force of medication coat, also can improve the corrosion resistance of said support.
The specific embodiment
Embodiment one; A kind of coating stent of medicine that prevents vascular restenosis and preparation method thereof; Said support is a cochrome, and support is covered with nanoparticle coating on being, said nanoparticle coating is rapamycin polylactic acid-glycollic acid (RPM-PLGA) nanoparticle coating.Said nanoparticle coating comprises pharmaceutical carrier and drug material, and said pharmaceutical carrier is polylactic acid-glycollic acid (PLGA), and said drug material is rapamycin (RPM), and the mass ratio of wherein said rapamycin and PLGA is 1:5.
Said PLGA comprises PLA and PGA, and the molar ratio 80:20 of said PLA and PGA, the molecular weight of said PLGA are 40000.
The method for preparing of said rapamycin polylactic acid-glycollic acid (RPM-PLGA) nanoparticle coating comprises the steps:
1., at first adopt water cutter engraving mode that said support is engraved as reticulate pattern hollow out tubular body.
2., treat that support engraving is accomplished after, through dichloromethane with said PLGA dissolving formation PLGA dichloromethane solution.
3., in the PLGA dichloromethane solution, add rapamycin; And fully dissolving in the PLGA dichloromethane solution; After treating the rapamycin dissolving, the PLGA dichloromethane solution that is dissolved with rapamycin is placed under the condition of ice bath, adopt Ultrasonic Cell Disruptor emulsifying 10 min to process suspension again.
4., after suspension preparation accomplishes, in said suspension, add 2% polyvinyl alcohol (PVA) aqueous solution, through magnetic agitation, the speed of magnetic agitation is 300 r/min when adding the PVA aqueous solution; And then adopt Ultrasonic Cell Disruptor emulsifying 10 min, make emulsion;
5., after emulsion preparation accomplishes, under 40 ℃ of temperature, with the emulsion decompression and the rotary evaporation that make, make in the emulsion the dichloromethane volatilization fully, and then make the nanometer colloid dispersion;
6., the coupling agent of adding 1% in said nanometer colloid dispersion; The support of engraving impregnated in 5 min in the nanometer colloid dispersion that adds coupling agent; Make said coating stent of medicine, freezing and dried 10 h with prepared coating stent of medicine then, and in 4 ℃ of preservations.
Wherein, said coupling agent is a silanes.
Said drug material and pharmaceutical carrier exist with two kinds of forms simultaneously: a kind of is that said pharmaceutical carrier wraps up rapamycin in it, and another kind is that said pharmaceutical carrier does not wrap up rapamycin.This kind medicine carrying mode makes the rapamycin rate of release have selectivity and controllability, thereby brings into play Drug therapy efficient better.
Embodiment two, and a kind of coating stent of medicine that prevents vascular restenosis and preparation method thereof, said support are cochrome, and support is covered with nanoparticle coating on being, said nanoparticle coating is a paclitaxel polylactic acid-glycollic acid nanoparticle coating.Said nanoparticle coating comprises pharmaceutical carrier and drug material, and said pharmaceutical carrier is polylactic acid-glycollic acid (PLGA), and said drug material is a paclitaxel, and wherein the mass ratio of paclitaxel and PLGA is 1:6.
Said PLGA comprises PLA and PGA, and the molar ratio 80:20 of said PLA and PGA, the molecular weight of said PLGA are 40000.
The method for preparing of said paclitaxel polylactic acid-glycollic acid nanoparticle coating comprises the steps:
1., at first adopt water cutter engraving mode that said support is engraved as reticulate pattern hollow out tubular body.
2., treat that support engraving is accomplished after, through dichloromethane with said PLGA dissolving formation PLGA dichloromethane solution.
3., in the PLGA dichloromethane solution, add paclitaxel; And fully dissolving in the PLGA dichloromethane solution; After treating the paclitaxel dissolving, the PLGA dichloromethane solution that is dissolved with paclitaxel is placed under the condition of ice bath, adopt Ultrasonic Cell Disruptor emulsifying 10 min to process suspension again.
4., after suspension preparation accomplishes, in said suspension, add 2% polyvinyl alcohol (PVA) aqueous solution, through magnetic agitation, the speed of magnetic agitation is 300 r/min when adding the PVA aqueous solution; And then adopt Ultrasonic Cell Disruptor emulsifying 10 min, make emulsion;
5., after emulsion preparation accomplishes, under 40 ℃ of temperature, with the emulsion decompression and the rotary evaporation that make, make in the emulsion the dichloromethane volatilization fully, and then make the nanometer colloid dispersion;
6., the coupling agent of adding 1% in said nanometer colloid dispersion; The support of engraving impregnated in 5 min in the nanometer colloid dispersion that adds coupling agent; Make said coating stent of medicine, freezing and dried 10 h with prepared coating stent of medicine then, and in 4 ℃ of preservations.
Wherein, said coupling agent is any in silanes, titanate ester and the aluminic acid chemical compound.
Said drug material and pharmaceutical carrier exist with two kinds of forms simultaneously: a kind of is that said pharmaceutical carrier wraps up paclitaxel in it, and another kind is that said pharmaceutical carrier does not wrap up paclitaxel.This kind medicine carrying mode makes the paclitaxel rate of release have selectivity and controllability, thereby brings into play Drug therapy efficient better.
Embodiment three, and a kind of coating stent of medicine that prevents vascular restenosis and preparation method thereof, said support are cochrome, and support is covered with nanoparticle coating on being.Said nanoparticle coating comprises pharmaceutical carrier and drug material, and said pharmaceutical carrier is polylactic acid-glycollic acid (PLGA), and said drug material is the mixture of rapamycin and paclitaxel, and wherein, the mixed proportion of rapamycin and paclitaxel is 1:1.Said drug material and pharmaceutical carrier mass ratio be 1:6.Said PLGA comprises PLA and PGA, and the molar ratio 80:20 of said PLA and PGA, the molecular weight of said PLGA are 40000.
The method for preparing of said nanoparticle coating comprises the steps:
1., at first adopt water cutter engraving mode that said support is engraved as reticulate pattern hollow out tubular body.
2., treat that support engraving is accomplished after, through dichloromethane with said PLGA dissolving formation PLGA dichloromethane solution.
3., in the PLGA dichloromethane solution, add rapamycin and paclitaxel; And fully dissolving in the PLGA dichloromethane solution; After treating the dissolving of rapamycin and paclitaxel; The PLGA dichloromethane solution that is dissolved with rapamycin and paclitaxel is placed under the condition of ice bath, adopt Ultrasonic Cell Disruptor emulsifying 10 min to process suspension again.
4., after suspension preparation accomplishes, in said suspension, add 2% polyvinyl alcohol (PVA) aqueous solution, through magnetic agitation, the speed of magnetic agitation is 300 r/min when adding the PVA aqueous solution; And then adopt Ultrasonic Cell Disruptor emulsifying 10 min, make emulsion;
5., after emulsion preparation accomplishes, under 40 ℃ of temperature, with the emulsion decompression and the rotary evaporation that make, make in the emulsion the dichloromethane volatilization fully, and then make the nanometer colloid dispersion;
6., the coupling agent of adding 1% in said nanometer colloid dispersion; The support of engraving impregnated in 5 min in the nanometer colloid dispersion that adds coupling agent; Make said coating stent of medicine, freezing and dried 10 h with prepared coating stent of medicine then, and in 4 ℃ of preservations.
Wherein, said coupling agent is any in silanes, titanate ester and the aluminic acid chemical compound.
Said drug material and pharmaceutical carrier exist with two kinds of forms simultaneously: a kind of is that said pharmaceutical carrier wraps up drug material in it, and another kind is a not packaging medicine material of said pharmaceutical carrier.This kind medicine carrying mode makes the drug material rate of release have selectivity and controllability, thereby brings into play Drug therapy efficient better.
Using when of the present invention, at first said coating stent of medicine be enclosed within on the brief little sacculus of conduit, with conduit insert that the patient has blocked or serious narrow blood vessel in.Begin the dilatation balloon that pressurizes, when balloon expandable, said coating stent of medicine will be strutted, and is attached on the blood vessel wall at obstruction place, to keep vessel expansion.Said support is degraded through the pharmaceutical carrier in its surperficial nanoparticle coating gradually, makes the said drug material release medicine slow and lasting at the angiostenosis place, thereby reduces the probability of vascular restenosis.
In sum, a kind of coating stent of medicine that prevents vascular restenosis and preparation method thereof, said medication coat Chinese medicine material are one or both mixing in rapamycin or the paclitaxel.Said pharmaceutical carrier is PLGA, and PLGA is a kind of good biocompatibility, biodegradable polyester family macromolecule, and its degradation in vivo becomes lactic acid and hydroxyacetic acid, finally is metabolized to water and carbon dioxide, avirulence and non-immunogenicity.
PLGA is prepared to the nanoparticle size, and PLGA nanoparticle size is even, and particle size distribution range is narrow; Concentrate and be distributed in 100 ~ 200 nm; Have the favorable biological degradability and the compatibility, and degradation speed is controlled, has improved the bioavailability of medication coat; Significantly improve drug material in the endovascular holdup time, kept the long-time in vivo steady plasma-drug concentration of medicine.
Said coupling agent can improve the adhesion of medication coat and support, avoids said medication coat to come off, and delays the degradation process of pharmaceutical carrier simultaneously.Said coupling agent reacts at said rack surface, not only can improve the adhesive force of medication coat, also can improve the corrosion resistance of said support.
The above embodiment has only expressed several kinds of embodiments of the present invention, and it describes comparatively concrete and detailed, but can not therefore be interpreted as the restriction to claim of the present invention.Should be pointed out that for the person of ordinary skill of the art under the prerequisite that does not break away from the present invention's design, can also make some distortion and improvement, these all belong to protection scope of the present invention.Therefore, the protection domain of patent of the present invention should be as the criterion with accompanying claims.
Claims (6)
1. one kind prevents coating stent of medicine of vascular restenosis and preparation method thereof; It is characterized in that: be covered with nanoparticle coating on the said support; Said nanoparticle coating comprises pharmaceutical carrier and drug material; Said pharmaceutical carrier is polylactic acid-glycollic acid PLGA, and said drug material is one or both in rapamycin RPM or the paclitaxel, and the mass ratio of said drug material and pharmaceutical carrier is 1:3～10;
The method for preparing of said coating stent of medicine comprises following step:
1., at first adopt water cutter engraving mode that said support is engraved as reticulate pattern hollow out tubular body;
2., treat that support engraving is accomplished after, through dichloromethane with said polylactic acid-glycollic acid PLGA dissolving formation PLGA dichloromethane solution;
3., in the PLGA dichloromethane solution, add said drug material; And fully dissolving in the PLGA dichloromethane solution; After treating said drug material dissolving; The PLGA dichloromethane solution that is dissolved with drug material is placed under the condition of ice bath, adopt Ultrasonic Cell Disruptor emulsifying 8～12 min to process suspension again;
4., after suspension preparation accomplishes, in said suspension, slowly add 1.5～2.5% PVAC polyvinylalcohol aqueous solutions, through magnetic agitation, the speed of magnetic agitation is 300 r/min when adding the PVA aqueous solution; And then adopt Ultrasonic Cell Disruptor emulsifying 8～12 min, make emulsion;
5., after emulsion preparation accomplishes, under 35～45 ℃ of temperature, with the emulsion decompression and the rotary evaporation that make, make in the emulsion the dichloromethane volatilization fully, and then make the nanometer colloid dispersion;
6., in said nanometer colloid dispersion, add 0.8～1.2% coupling agent; The support of engraving impregnated in 4～6 min in the nanometer colloid dispersion that adds coupling agent; Make coating stent of medicine; Then 10～12 h are handled in prepared coating stent of medicine lyophilization, after finishing dealing with, in 4 ℃ of preservations.
2. coating stent of medicine that prevents vascular restenosis according to claim 1 and preparation method thereof is characterized in that: said polylactic acid-glycollic acid PLGA comprises PLA and PGA, molar ratio 75～85:15～25 of said PLA and PGA.
3. coating stent of medicine that prevents vascular restenosis according to claim 2 and preparation method thereof; It is characterized in that: the optimum molar ratio of said PLA and PGA is 80:20; When the optimum molar ratio of said PLA and PGA, said polylactic acid-glycollic acid PLGA molecular weight is 35000～55000.
4. coating stent of medicine that prevents vascular restenosis according to claim 1 and preparation method thereof is characterized in that: said coupling agent is a kind of in silanes, titanate ester and the aluminic acid chemical compound.
5. coating stent of medicine that prevents vascular restenosis according to claim 1 and preparation method thereof is characterized in that: said support is the cochrome support.
6. coating stent of medicine that prevents vascular restenosis according to claim 1 and preparation method thereof is characterized in that: said rapamycin and paclitaxel mixed proportion are 1:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101590609A CN102657899B (en) | 2012-05-22 | 2012-05-22 | Medicament coating stent capable of preventing blood vessel restenosis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101590609A CN102657899B (en) | 2012-05-22 | 2012-05-22 | Medicament coating stent capable of preventing blood vessel restenosis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102657899A true CN102657899A (en) | 2012-09-12 |
| CN102657899B CN102657899B (en) | 2013-11-13 |
Family
ID=46767562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101590609A Active CN102657899B (en) | 2012-05-22 | 2012-05-22 | Medicament coating stent capable of preventing blood vessel restenosis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102657899B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015172664A1 (en) * | 2014-05-13 | 2015-11-19 | 奚廷斐 | Method for preparing surface coating with reduced degradation rate of biodegradable magnesium alloy vascular stent |
| CN105709279A (en) * | 2016-01-19 | 2016-06-29 | 中国医科大学附属第一医院 | PLGA-S1P nanometer material and preparation method of PLGA-S1P nanometer coating stent |
| CN106512083A (en) * | 2016-10-14 | 2017-03-22 | 湖北大学 | Medical titanium alloy preparation method |
| CN107335100A (en) * | 2017-07-31 | 2017-11-10 | 首都医科大学附属北京安贞医院 | A kind of CABG prevents bridge reangiostenosis system |
| CN108096583A (en) * | 2017-12-17 | 2018-06-01 | 宋振川 | The preparation method of the cancer target nanoparticulate carriers of mammary cancer chemotherapy drug MTDH siRNA is loaded with altogether |
| CN108744233A (en) * | 2018-06-28 | 2018-11-06 | 山东吉威医疗制品有限公司 | A kind of medicine balloon dilating catheter and its technique |
| CN109718459A (en) * | 2019-01-03 | 2019-05-07 | 苏州优医港科技有限公司 | Medicinal balloon catheter and preparation method thereof |
| CN115006605A (en) * | 2022-07-20 | 2022-09-06 | 苏州中天医疗器械科技有限公司 | Drug coating balloon and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101091806A (en) * | 2006-06-20 | 2007-12-26 | 天津市凯迪亚医疗器械有限公司 | Slow release coating layer of degradable medication for bracket of coronary artery |
| US20080118544A1 (en) * | 2006-11-20 | 2008-05-22 | Lixiao Wang | Drug releasing coatings for medical devices |
| WO2010021883A2 (en) * | 2008-08-20 | 2010-02-25 | Abbott Cardiovascular Systems Inc. | Biosoluble coating with linear over time mass loss |
| CN101869723A (en) * | 2009-04-27 | 2010-10-27 | 赵菁 | Composite medicament stent for inhibiting cardiovascular restenosis and preparation method |
-
2012
- 2012-05-22 CN CN2012101590609A patent/CN102657899B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101091806A (en) * | 2006-06-20 | 2007-12-26 | 天津市凯迪亚医疗器械有限公司 | Slow release coating layer of degradable medication for bracket of coronary artery |
| US20080118544A1 (en) * | 2006-11-20 | 2008-05-22 | Lixiao Wang | Drug releasing coatings for medical devices |
| WO2010021883A2 (en) * | 2008-08-20 | 2010-02-25 | Abbott Cardiovascular Systems Inc. | Biosoluble coating with linear over time mass loss |
| CN101869723A (en) * | 2009-04-27 | 2010-10-27 | 赵菁 | Composite medicament stent for inhibiting cardiovascular restenosis and preparation method |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015172664A1 (en) * | 2014-05-13 | 2015-11-19 | 奚廷斐 | Method for preparing surface coating with reduced degradation rate of biodegradable magnesium alloy vascular stent |
| CN105709279A (en) * | 2016-01-19 | 2016-06-29 | 中国医科大学附属第一医院 | PLGA-S1P nanometer material and preparation method of PLGA-S1P nanometer coating stent |
| CN105709279B (en) * | 2016-01-19 | 2019-03-05 | 中国医科大学附属第一医院 | The preparation method of PLGA-S1P nano material and PLGA-S1P nano coating bracket |
| CN106512083A (en) * | 2016-10-14 | 2017-03-22 | 湖北大学 | Medical titanium alloy preparation method |
| CN106512083B (en) * | 2016-10-14 | 2019-09-24 | 湖北大学 | A kind of preparation method of medical titanium alloy |
| CN107335100A (en) * | 2017-07-31 | 2017-11-10 | 首都医科大学附属北京安贞医院 | A kind of CABG prevents bridge reangiostenosis system |
| CN108096583A (en) * | 2017-12-17 | 2018-06-01 | 宋振川 | The preparation method of the cancer target nanoparticulate carriers of mammary cancer chemotherapy drug MTDH siRNA is loaded with altogether |
| CN108744233A (en) * | 2018-06-28 | 2018-11-06 | 山东吉威医疗制品有限公司 | A kind of medicine balloon dilating catheter and its technique |
| CN109718459A (en) * | 2019-01-03 | 2019-05-07 | 苏州优医港科技有限公司 | Medicinal balloon catheter and preparation method thereof |
| CN115006605A (en) * | 2022-07-20 | 2022-09-06 | 苏州中天医疗器械科技有限公司 | Drug coating balloon and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102657899B (en) | 2013-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102657899B (en) | Medicament coating stent capable of preventing blood vessel restenosis and preparation method thereof | |
| EP2213313B1 (en) | An arsenic trioxide medical elution scaffold | |
| Chen et al. | Mesoporous silica nanoparticles for tissue‐engineering applications | |
| CN101869514B (en) | Controlled drug-release composition and drug-releasable medical device | |
| US20120083734A1 (en) | Balloon catheter comprising pressure sensitive microparticles | |
| Kapoor et al. | PLGA: a unique polymer for drug delivery | |
| JP5106415B2 (en) | Nanoparticle emitting medical device | |
| Vilos et al. | Therapeutic strategies based on polymeric microparticles | |
| JP2007153896A (en) | Compound of nanoparticle and/or microparticle for treating vascular disease based on topical injection | |
| JP2009102418A (en) | Composition and method for coating medical device | |
| WO2009113605A1 (en) | Drug elution-type catheter and method for manufacturing the drug elution-type catheter | |
| WO2015070814A1 (en) | Drug-eluting balloon and preparation method therefor | |
| WO2011024831A1 (en) | Medical device for placement into a lumen and manufacturing method thereof | |
| CN101879102A (en) | Groove carrying-type coating decomposable drug eluting stent | |
| He et al. | Localized multidrug co-delivery by injectable self-crosslinking hydrogel for synergistic combinational chemotherapy | |
| CN112704686B (en) | Preparation method of calcium phosphate-rapamycin composite medicine, preparation method of medicine coating balloon and medicine coating balloon | |
| CN103566415A (en) | Human body blood vessel implant with coatings on two surfaces and manufacturing method thereof | |
| Yan et al. | In vivo biodistribution for tumor targeting of 5-fluorouracil (5-FU) loaded N-succinyl-chitosan (Suc-Chi) nanoparticles | |
| CN114209960A (en) | Medicine balloon and preparation method and application thereof | |
| Yang et al. | Intravascular site-specific delivery of a therapeutic antisense for the inhibition of restenosis | |
| Hou et al. | Preparation and in vitro evaluation of an ultrasound-triggered drug delivery system: 10-Hydroxycamptothecin loaded PLA microbubbles | |
| CN101959542B (en) | Drug delivery system | |
| CN103990185A (en) | Carrageenan and gelatin microsphere embolization agent and preparation method thereof | |
| CN103877625B (en) | PLGA (poly(lactic-co-glycolic acid))/bletilla composite microsphere for embolism and preparation method thereof | |
| Okamoto et al. | Fabrication of radiopaque drug-eluting beads based on lipiodol/biodegradable-polymer for image-guided transarterial chemoembolization of unresectable hepatocellular carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |